GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: hepatic fat stopped being a problem at week 91 — 66 comments in the full submission. View in context.
761
c/survodutide·submitted 9 months ago by u/elin_ferrari

small win: hepatic fat stopped being a problem at week 91

Cautionbranch of 8 comments

Check-in as promised in the title: small win: hepatic fat stopped being a problem at week 91. Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use. Independent purity results for this compound are very sparse across the whole site, which means any impression…

Read the full submission and all 66 comments →

This branch

8 comments, started 9 months ago
u/kaia_cabrera39 points·9 months ago·edited

The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.

replysharereportpermalink
u/liver_enzyme_lizMOD16 points·9 months ago

Independent result logged. There are almost none for this compound, so it is genuinely valuable.

replysharereportpermalink
u/ismael_nwosu5 points·9 months ago

phase 2 in liver disease is a different evidence question from weight

replysharereportpermalink
load more comments (2) →
u/elin_ferrariOP30 points·9 months ago

a liver endpoint is not a weight endpoint with better marketing

replysharereportpermalink
u/liv_vukovic14 points·9 months ago

fibrosis improvement without worsening steatohepatitis is the phrase to learn

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/survodutide

Survodutide-specific discussion: glucagon-receptor co-agonism, the hepatic fat and MASH resolution data, and how the side-effect profile compares with GIP-based dual agonism. Small community, high signal.

12kmembers
62submissions
Feb 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
More in c/survodutide
c/survodutide rules
  1. Glucagon co-agonism has a distinct safety story. Do not generalise from tirzepatide.
  2. MASH claims need the trial and the biopsy endpoint.
  3. Not approved. Descriptive posts only.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/liver_enzyme_lizu/trialwatch_theo
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →